Metabolic syndrome and nonalcoholic fatty liver disease in a Spanish population

Abstract

The MetS is quite frequent in the general population, although its prevalence varies considerably according to the criteria used for its definition. The MetS is associated with NAFLD, with the WHO definition being the best to determine its presence, probably because of the inclusion of insulin resistance as a main component. Unification of criteria is needed to adequately compare the prevalence of MetS and its relationship with NAFLD in different population groups.

Metabolic syndrome association with fibrosis development in chronic hepatitis B virus inactive carriers

“…This higher rate is probably due to different reasons, mainly the characteristics of the study population; the prevalence of MS in Spanish population is 15-34%, depending on the criteria used. 6 Therefore, the prevalence in our study for inactive HBV carriers is similar with that reported in general population of Western countries. 28 Transient elastography has been shown to correlate with fibrosis in CHB.…”

“…also estimated that the prevalence of MS was 11% in CHB and 20% in controls; we found a prevalence of 24%. This higher rate is probably due to different reasons, mainly the characteristics of the study population; the prevalence of MS in Spanish population is 15–34%, depending on the criteria used . Therefore, the prevalence in our study for inactive HBV carriers is similar with that reported in general population of Western countries …”

“…Emerging data support a role for lipid and glucose metabolism in fibrosis development and hepatocellular carcinogenesis . The prevalence of non‐alcoholic fatty liver disease among patients with MS is 43–64% (depending on the definition of MS used), in Spanish population . In chronic hepatitis C infection, the association with hepatic steatosis is well known; in these patients, hepatic steatosis is present in up to 30–70% of patients and is a risk factor for liver disease progression and it decreases the response to antiviral therapy, independently of hepatitis C genotypes .…”

“…4,5 The prevalence of non-alcoholic fatty liver disease among patients with MS is 43-64% (depending on the definition of MS used), in Spanish population. 6 In chronic hepatitis C infection, the association with hepatic steatosis is well known; 7 in these patients, hepatic steatosis is present in up to 30-70% of patients and is a risk factor for liver disease progression 8 and it decreases the response to antiviral therapy, independently of hepatitis C genotypes. 9 This association in HBV infection has not been demonstrated, despite several studies have focused in this problem last years.…”

Non-Alcoholic Fatty Liver Disease, a Marker of Subclinical Atherosclerosis Applicable Only to Metabolic Syndrome?: Time to Organize the Connection between Metabolism and Atherosclerosis

“…In this context, it is noteworthy to recognize that the patients without metabolic syndrome in this report tended to be more obese and have higher levels of low-density lipoprotein-cholesterol and triglycerides 14). Furthermore, a previous report has commented that the prevalence of metabolic syndrome and its relationship with the presence/absence of NAFLD may vary from criterion-to-criterion 19). Indeed, the current diagnosis of metabolic syndrome is still not unified20-22) and the basic concepts do differ from each models of definition.…”